Cosmetics Adverse Events Under Spotlight In FDA Transparency Push
This article was originally published in The Rose Sheet
Executive Summary
FDA’s release of AER data removes some secrecy surrounding cosmetic product adverse events but could create a false alarm about the industry. The data dump comes as Congress is considering legislation that would mandate that cosmetics firms provide FDA with reports of serious adverse events they receive.